EMA Authorised: Jemperli (dostarlimab) — GlaxoSmithKline Trading Services Limited

View source ↗

Summary

EMA has authorised Jemperli (dostarlimab) for endometrial neoplasms, expanding therapeutic options in this area.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Neoplasms

Drugs mentioned

• JEMPERLI (DOSTARLIMAB)

Snippet

Status: Authorised. Therapeutic area: Endometrial Neoplasms. MAH: GlaxoSmithKline Trading Services Limited. Decision date: 04/06/2026